Abstract: A multilayer structure includes an oriented polyethylene film and a barrier layer disposed on at least one surface of the oriented polyethylene film. The oriented polyethylene film comprises at least one layer having a polymer blend of at least one ethylene-based polymer and at least one ethylene acid copolymer. The ethylene-based polymer has a density of 0.910 to 0.960 g/cm3 and a melt index (I2) of 0.3 to 10 g/10 mins. The ethylene acid copolymer is the polymerized reaction product of ethylene monomer, monomer selected from the group consisting of monocarboxylic acids, dicarboxylic acids, anhydrides, and monoesters thereof, and optionally alkyl acrylate monomer. From 0 to 90 mol. % of total acid units of the ethylene acid copolymer may be neutralized with a neutralizing salt solution.

Abstract: The present invention discloses a process for forming a biaxially oriented film. The process includes first selecting a polyolefin resin wherein said polyolefin resin comprises a linear low density polyethylene resin characterized by having from 9 to 35 weight percent of the total weight of linear low density polyethylene resin eluting from a CEF at a temperature greater than 97.0° C.; and further characterized by having a CDR of from 33 to 80 and a Mw Ratio of from 0.15 to 0.45. Next a film is formed from the polyolefin resin selected in the first step. Finally the film formed in the second step is oriented in a sequential manner. The films produced by this process are characterized by having an ultimate elongation at least 1.5 times greater in the MD as compared to the CD and the 2% secant modulus is a least 1.25 times greater in the CD as compared to the MD.

Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.

Abstract: It provides laminates and articles formed from such laminates. In one aspect, a laminate comprises (a) a biaxially oriented polyethylene (BOPE) film comprising a polyethylene composition, wherein the polyethylene composition has a density of 0.910 to 0.940 g/cm3, an MWHDF>95 greater than 135 kg/mol and an IHDF >95 greater than 42 kg/mol, wherein the BOPE film comprises at least 50 weight percent of the polyethylene composition based on the weight of the BOPE film; (b) a barrier adhesive layer comprising polyurethane; and (c) a polyethylene film, wherein the barrier adhesive layer adheres the BOPE film to the polyethylene film and wherein the laminate has an oxygen gas transmission rate of 700 cc/[m2-day] or less when measured according to ASTM D3985-05.

Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.

Abstract: The coextruded multilayer film has at least two layers, including a sealant layer and a second layer in contact with the sealant layer. The sealant layer contains (A) a first ethylene-based polymer having a density from 0.865 g/cc to 0.930 g/cc and a melt index from 0.5 g/10 min to 25 g/10 min; (B) an unsaturated primary fatty acid amide having a melting point of 100° C. or less; and (C) a saturated primary fatty acid amide having a melting point greater than 100° C. The unsaturated primary fatty acid amide and the saturated primary fatty acid amide have a weight ratio of from 3:1 to 1:6. The second layer contains a second ethylene-based polymer. The present disclosure also provides a laminate containing said sealant layer.

Abstract: A biaxially-oriented polyethylene (BOPE) multilayer film comprises a skin layer with a matte surface and a core, the skin layer with a matte surface comprising, in weight percent (wt %) based upon the weight of the skin layer: (1) from 20 to 80 wt % of an ethylene-based polymer, and (2) from 80 to 20 wt % of a propylene-based polymer; each of the ethylene-based polymer and the propylene-based polymer having a storage modulus, with a difference between the storage modulus of the ethylene-based polymer and the propylene-based polymer of greater than 40 megaPascals (MPa) at 110° C., and greater than 18 MPa at 120° C.

Abstract: A first oriented film comprising a first polyethylene composition which comprises: from 20 to 50 wt % of a first linear low density polyethylene polymer having a density greater than 0.925 g/cc and an 12 lower than 2 g/10min; and from 80 to 50 wt % of a second linear low density polyethylene polymer having a density lower than or equal to 0.925 g/cc and an 12 greater than or equal to 2 g/10min; wherein the first polyethylene composition has an 12 from 0.5 to 10 g/10min and a density from 0.910 to 0.940 g/cc is provided.

Abstract: The coextruded multilayer film has at least two layers, including a sealant layer and a second layer in contact with the sealant layer. The sealant layer contains (A) a first ethylene-based polymer having a density from 0.865 g/cc to 0.930 g/cc and a melt index from 0.5 g/10 min to 25 g/10 min; (B) an unsaturated primary fatty acid amide having a melting point of 100° C. or less; and (C) a saturated primary fatty acid amide having a melting point greater than 100° C. The unsaturated primary fatty acid amide and the saturated primary fatty acid amide have a weight ratio of from 3:1 to 1:6. The second layer contains a second ethylene-based polymer. The present disclosure also provides a laminate containing said sealant layer.

Abstract: A selective catalytic reduction (SCR) system is disclosed. The SCR system may include a mixing tube with a mixing tube inlet; a diesel exhaust fluid (DEF) injector proximate to the mixing tube inlet; and a flow control device proximate to the mixing tube inlet, wherein the flow control device is positioned within the mixing tube or affixed to the mixing tube inlet, and wherein the flow control device includes a plurality of vanes arranged around a center of the flow control device.

Abstract: In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

Abstract: Provided is a polymer blend that can be used in films, packages, and fibers. In one aspect, a polymer blend comprises an ethylene-based polymer, and one or more compounds of formula (I), wherein n is 6 to 24.

Abstract: Provided is a coextruded multilayer film. The coextruded multilayer film has at least two layers, including a sealant layer and a second layer in contact with the sealant layer. The sealant layer contains (A) a first ethylene-based polymer having a density from 0.865 g/cc to 0.930 g/cc and a melt index from 0.5 g/10 min to 25 g/10 min; (B) an unsaturated primary fatty acid amide having a melting point of 100° C. or less; and (C) a diprotic fatty acid having a melting point greater than 100° C. and a decomposition temperature greater than 200° C. The second layer contains a second ethylene-based polymer. Also provided is a laminate containing said sealant layer.

Abstract: An aftertreatment module is disclosed. The aftertreatment module may include a housing and a mounting plate within the housing that forms an inlet chamber and an outlet chamber. The aftertreatment module may include an inlet for exhaust gas from a combustion engine to flow into the inlet chamber and an outlet through a top plate of the housing for the exhaust gas to flow from the outlet chamber, wherein the outlet comprises a plurality of perforations. The aftertreatment module may include an outlet sensor mounted on the outlet to obtain information relating to the exhaust gas as the exhaust gas flows from the outlet chamber and a set of catalysts mounted to the mounting plate to treat the exhaust gas as the exhaust gas flows from the inlet chamber to the outlet chamber. The aftertreatment module may include a drain port through a side plate of the housing.

Abstract: Embodiments of the present invention relate to biaxially oriented, multilayer polyethylene films and to laminates and articles formed therefrom. In one aspect, a biaxially oriented, multilayer polyethylene film comprises Layer A which is a sealant layer p having a top facial surface and a bottom facial surface and comprising a first polyethylene, wherein the first polyethylene has a density of at least 0.900 g/cm3, an IHDF>95 of 20-60 kg/mol, and a MWHDF>95 of greater than 130 kg/mol, wherein Layer A comprises at least 50 weight percent of the first polyethylene based on the weight of Layer A, and Layer B having a top facial surface and a bottom facial surface, wherein Layer B comprises one or more additional polyethylenes, and wherein the top facial surface of Layer B is in adhering contact with a bottom facial surface of Layer A, wherein the density of the first polyethylene is at least 0.002 g/cm3 less than the density of Layer B.

Abstract: A selective catalytic reduction (SCR) system is disclosed. The SCR system may include a mixing tube with a mixing tube inlet; a diesel exhaust fluid (DEF) injector proximate to the mixing tube inlet; and a flow control device proximate to the mixing tube inlet, wherein the flow control device is positioned within the mixing tube or affixed to the mixing tube inlet, and wherein the flow control device includes a plurality of vanes arranged around a center of the flow control device.

Abstract: An aftertreatment module is disclosed. The aftertreatment module may include a housing and a mounting plate within the housing that forms an inlet chamber and an outlet chamber. The aftertreatment module may include an inlet for exhaust gas from a combustion engine to flow into the inlet chamber and an outlet through a top plate of the housing for the exhaust gas to flow from the outlet chamber, wherein the outlet comprises a plurality of perforations. The aftertreatment module may include an outlet sensor mounted on the outlet to obtain information relating to the exhaust gas as the exhaust gas flows from the outlet chamber and a set of catalysts mounted to the mounting plate to treat the exhaust gas as the exhaust gas flows from the inlet chamber to the outlet chamber. The aftertreatment module may include a drain port through a side plate of the housing.

Abstract: A multilayer structure comprising at least one skin sealant layer, wherein the skin layer comprises a polyethylene having a crystallinity, CS; a tie layer which comprises a first polyethylene having a crystallinity, CT, wherein the tie layer is adhered to the skin layer; and a bulk layer which comprises a second polyethylene having a crystallinity, CB, wherein the tie layer is disposed between the bulk layer and the skin sealant layer; wherein CB>CT>CS; and wherein the layers are coextruded and the multilayer structure oriented by a semi-molten orientation process is provided. Also provided is a laminate comprising the multilayer structure and articles comprising the laminate.

Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.

Abstract: An exhaust gas aftertreatment system is disclosed. The system may include an inlet to receive an exhaust gas produced by an engine and a first section to receive the exhaust gas from the inlet. The system may include a mixing tube to receive the exhaust gas from the first section and a reductant injector to inject a reductant into the mixing tube. The system may include a second section to receive the exhaust gas from the mixing tube and to facilitate mixing of the reductant and the exhaust gas after the exhaust gas exits the mixing tube and a diffuser to receive the exhaust gas from the second section. The system may include a plurality of catalysts to receive the exhaust gas from the diffuser and at least one outlet to receive the exhaust gas from the plurality of catalysts.